Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 3/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.44 |
| ▸ | SHBG | P04278 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL219127 | 1.00 | MBOAT4 (0.62) | MBOAT4CYP19A1CDK5CDK5R1NR1I3 | |
| SCHEMBL21176005 | 1.00 | MBOAT4 (0.62) | MBOAT4CYP19A1CDK5CDK5R1NR1I3 | |
| SCHEMBL1781352 | 1.00 | MBOAT4 (0.62) | MBOAT4CYP19A1CDK5CDK5R1NR1I3 | |
| SCHEMBL29688566 | 1.00 | MBOAT4 (0.62) | MBOAT4CYP19A1CDK5CDK5R1NR1I3 | |
| SCHEMBL3268576 | 0.81 | MBOAT4 (0.53) | MBOAT4CYP19A1CDK5CDK5R1NR1I3 | |
| SCHEMBL1788661 | 0.80 | MBOAT4 (0.46) | MBOAT4CYP19A1GRIN1GRIN2BSHBG | |
| SCHEMBL2186022 | 0.79 | CYP19A1 (0.55) | CYP19A1SHBG | |
| SCHEMBL1287860 | 0.79 | CYP19A1 (0.55) | CYP19A1SHBG | |
| SCHEMBL1287861 | 0.79 | CYP19A1 (0.55) | CYP19A1SHBG | |
| SCHEMBL9512557 | 0.79 | CYP19A1 (0.55) | CYP19A1SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0468012-B1 | 17$g(b)-SUBSTITUTED-4-AZA-5$g(a)-ANDROSTAN-3-ONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | PHARMACIA SPA (IT) | 1995-09-20 | — | — | EP | claimed |
| EP-0649431-A4 | 17-AMINO SUBSTITUTED 4-AZASTEROID 5-G(A)-REDUCTASE INHIBITORS. | — | 1995-05-03 | — | — | EP | claimed |
| EP-0649431-A1 | 17-AMINO SUBSTITUTED 4-AZASTEROID 5$g(a)-REDUCTASE INHIBITORS | MERCK & CO. INC. (US) | 1995-04-26 | — | — | EP | claimed |
| WO-1991012261-A1 | 17β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FARMITALIA CARLO ERBA S.R.L. (IT) | 1991-08-22 | — | — | WO | claimed |
| US-20190224214-A1 | HUMAN GHRELIN O-ACYLTRANSFERASE INHIBITORS | SYRACUSE UNIVERSITY (US) | 2019-07-25 | — | — | US | disclosed |
| US-20080119503-A1 | Androgen receptor modulators and methods of use thereof | MERCK SHARP & DOHME CORP. | 2008-05-22 | — | — | US | disclosed |
| US-7351698-B2 | Androgen receptor modulators and methods of use thereof | MERCK & CO., INC. (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1868593-A2 | IMPROVED METHODS OF AND COMPOSITIONS FOR THE PREVENTION OF ANXIETY, SUBSTANCE ABUSE, AND DEPENDENCE | Hythiam, Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20060241107-A1 | Androgen receptor modulators and methods of use thereof | MERCK SHARP & DOHME LLC | 2006-10-26 | — | — | US | disclosed |
| WO-2006110642-A2 | IMPROVED METHODS OF AND COMPOSITIONS FOR THE PREVENTION OF ANXIETY, SUBSTANCE ABUSE, AND DEPENDENCE | HYTHIAM, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20050137256-A1 | Use of arachidonic acid as a method of increasing skeletal muscle mass | LLEWELLYN WILLIAM C (US) | 2005-06-23 | — | — | US | disclosed |
| US-6841573-B2 | Use of arachidonic acid as a method of increasing skeletal muscle mass | MOLECULAR NUTRITION (US) | 2005-01-11 | — | — | US | disclosed |
| EP-0462662-A2 | 17beta-N-monosubstituted adamantyl/norbornanyl carbamoyl-4-aza-5alpha-androst-1-en-3-ones and androstan-3-ones | MERCK & CO. INC. (US) | 1991-12-27 | — | — | EP | disclosed |
| EP-0462661-A2 | Novel 17beta-hydroxybenzoyl-4-aza-5alpha-androst-1-en-3-ones as testosterone reductase inhibitors | MERCK & CO. INC. (US) | 1991-12-27 | — | — | EP | disclosed |
| US-5061802-A | 17β-aminobenzoyl-4-aza-5α-androst-1-en-3-ones as benign prostatic hypertrophy agents | MERCK & CO. INC. (US) | 1991-10-29 | — | — | US | disclosed |
| US-5049562-A | Enzyme inhibitors, antiandrogens | MERCK & CO., INC. (US) | 1991-09-17 | — | — | US | disclosed |
| WO-1991012261-A1 | 17β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FARMITALIA CARLO ERBA S.R.L. (IT) | 1991-08-22 | — | — | WO | disclosed |
| US-4859681-A | 17 α-Acyl-4-aza-5a-androst-1-en-3-ones as 5 alpha-reductase inhibitors | MERCK & CO., INC. (US) | 1989-08-22 | — | — | US | disclosed |
| US-4760071-A | Enzyme inhibitor | MERCK & CO., INC. (US) | 1988-07-26 | — | — | US | disclosed |
| EP-0271219-A1 | Topical pharmaceutical composition containing 17-beta-methoxycarbonyl-4-methyl-4-aza-5-alpha-androst-1-en-3-one | MERCK & CO. INC. (US) | 1988-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241107-A1 | Androgen receptor modulators and methods of use thereof | SHBG, FSHR, AR | MBOAT4 883/4885CYP19A1 11/4885CDK5 2978/4885 |
| US-20190224214-A1 | HUMAN GHRELIN O-ACYLTRANSFERASE INHIBITORS | MBOAT4, LCAT, ACAT1 | MBOAT4 1/4885CYP19A1 66/4885CDK5 1727/4885 |
| US-20080119503-A1 | Androgen receptor modulators and methods of use thereof | SHBG, FSHR, AR | MBOAT4 883/4885CYP19A1 11/4885CDK5 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.